Testing of Intravenous Hemostatic Agents in a Novel Swine Model of Bleeding: Preliminary Results With FXa-PCPs

Abstract

The public reporting burden for this collection of information is estimated to average 1 hour por reaponse. including the time for reviewing instructions. aearching existing data sources, gatharin9 and maintaining the data needed. and completing and reviewing the collection of Information. Send comments regarding this burden estimate or any other aspect of thia collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reaports 10704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Rleapondenta should be aware that notwithstanding any other proviaion of law, no person shall be subject to any penalty for failing to comply with a collection of information if it doea not diaplay a currently valid 0M8 control number. PLEASE DO NOT RETURN YOUR PERFORMING ORGANIZATION NAME(S) AND ADORESSDESS). PERFORMING ORGANIZATION SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITORS ACRONYM(S)U ABSTRACTFinding an intravenous treatment that could assist endogenous clotting mechanisms is a major mission for military researchers. Herein, we report preliminary data on the efficacy of mixtures of highly purified blood coagulation factors (FVIIa and FXa) and phospholipids vesicles (PCPS) to reduce traumatic bleeding. A novel swine model was developed in which 1) bleeding times (BT) and coagulation function could be ascertained following multiple doses of drug administration; and, 2) an exsanguinating injury could subsequently be performed in the same animal, yielding screening information as to the effects of drug pretreatment of blood loss and survival. FXa-PCPS failed to reduce BT or enhance coagulation function and a dose-dependent hypotensive response. FVIIa-PCPS yielded no data suggestive of the profound potentiation of FVIIa activity by PCPS observed in previous in vitro testing.Further study of these drugs for the use of traumatic hemorrhage is not warranted. SUBJECT TERMS